The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma DOI Creative Commons

Yixin Ding,

Shasha Wang, Zhenkang Qiu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 31, 2023

Systemic therapy remains the primary therapeutic approach for advanced hepatocellular carcinoma (HCC). Nonetheless, its efficacy in achieving control of intrahepatic lesions is constrained. Hepatic arterial infusion chemotherapy (HAIC) a that combines localized treatment with systemic antitumor effects, which aim to effectively manage progression cancerous within liver, particularly patients portal vein tumor thrombosis (PVTT). Combining HAIC anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) immunotherapy anticipated emerge as novel aimed at augmenting response inside site and prolonged survival advantages. In order assess effectiveness, safety, applicability various modalities address potential molecular mechanisms underlying HAIC-sensitizing immunotherapy, we reviewed literature about combination anti-PD-1 mAb therapies.

Language: Английский

Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors DOI Creative Commons
Renguo Guan, Nan Zhang, Min Deng

et al.

International Journal of Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: March 28, 2024

Background: Lenvatinib plus Programmed Death-1 (PD-1) inhibitors (LEN-P) have been recommended in China for patients with advanced hepatocellular carcinoma (HCC). However, they provide limited survival benefits to extrahepatic metastases. We aimed investigate whether combining hepatic arterial infusion chemotherapy (HAIC) LEN-P could improve its efficacy. Materials and Methods: This multi-center cohort study included HCC metastases who received HAIC combined (HAIC-LEN-P group, n=127) or alone (n=103) as the primary systemic treatment between January 2019 December 2022. Baseline data were balanced using a one-to-one propensity score matching (PSM) inverse probability of weighting (IPTW). Results: After PSM, HAIC-LEN-P group significantly extended median overall (mOS) progression-free (mPFS), compared (mOS: 27.0 months vs. 9.0 months, P <0.001; mPFS: 8.0 3.0 =0.001). IPTW, mOS (hazard ratio (HR)=0.384, <0.001) mPFS (HR=0.507, higher than group. The group’s objective response rate was twice high that (PSM cohort: 67.3% 29.1%, IPTW 66.1% 27.8%, <0.001). Moreover, exhibited no noticeable increase percentages grade 3 4 adverse events ( >0.05). Conclusion: can efficacy may be an alternative management.

Language: Английский

Citations

16

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE DOI

Lingfeng Diao,

Chendong Wang, Ran You

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 39(4), P. 746 - 753

Published: Jan. 19, 2024

Abstract Background and Aim The study aims to investigate the efficacy safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib immune checkpoint inhibitors (ICIs) versus ICIs for hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) refractoriness. Methods Patients intermediate or advanced TACE‐refractory HCC who received without HAIC between 2020 2022 were retrospectively reviewed. tumor response, overall survival (OS), progression‐free (PFS), treatment‐related adverse events (TRAEs) evaluated compared two groups. Factors affecting OS PFS identified univariate multivariate Cox regression analyses. Results A total 121 patients enrolled, 58 assigned HAIC‐Len‐ICI group 63 Len‐ICI group. higher objective response rate disease control found in than (48.30% vs 23.80%, P = 0.005; 87.90% 69.80%, 0.02, respectively). median was 24.0 months 13.0 ( 0.001). 7.2 < Multivariable analyses suggested that presence cirrhosis, Child–Pugh B stage, therapy option prognostic factors PFS. incidences any grade 3/4 TRAEs both comparable Conclusions yielded better OS, PFS, ORR, DCR lenvatinib‐ICI refractory TACE, manageable events.

Language: Английский

Citations

11

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study DOI Creative Commons
Xu Chang, Xinge Li, Peng Sun

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: April 16, 2024

Abstract Background The treatment of hepatocellular carcinoma (HCC) patients exhibiting high-risk characteristics (Vp4, and/or bile duct invasion, tumor occupancy ≥ 50%) lacks standardized approaches and yields unfavorable results. This study endeavors to evaluate the safety, efficacy, prognostic impacts employing hepatic arterial infusion chemotherapy (HAIC), lenvatinib, humanized programmed death receptor-1 (PD-1) in HCC patients. Methods In this retrospective analysis, with features were treated either lenvatinib combined PD-1 (LEN-PD1) or a combination HAIC, (HAIC-LEN-PD1). assessed antitumor efficacy by calculating overall survival (OS), progression-free (PFS), objective response rate (ORR), disease control (DCR). Treatment-related adverse events (TRAEs) analyzed assess safety profiles. Results Between June 2019 September 2022, total 61 included LEN-PD1 group, while 103 enrolled HAIC-LEN-PD1 group. OS was 9.8 months whereas group exhibited significantly longer median 19.3 (HR = 0.43, p < 0.001). Furthermore, PFS notably extended compared (9.6 vs. 4.9 months, HR 0.48, Patients had higher ORR DCR according modified RECIST (76.7% 23.0%, 0.001; 92.2% 72.1%, HAIC-LEN-HAIC led more than most which tolerable controllable. Conclusion Lenvatinib, HAIC showed safe promising anti-tumor activity alone for features.

Language: Английский

Citations

10

The current status and future of targeted-immune combination for hepatocellular carcinoma DOI Creative Commons

Liyuan Hao,

Shenghao Li,

Fanghang Ye

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 5, 2024

Hepatocellular carcinoma (HCC) is one of the most common cancers and third leading cause death worldwide. surgery, transarterial chemoembolization (TACE), systemic therapy, local ablation radiotherapy, targeted drug therapy with agents such as sorafenib. However, tumor microenvironment liver cancer has a strong immunosuppressive effect. Therefore, new treatments for are still necessary. Immune checkpoint molecules, programmed death-1 (PD-1), death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), along high levels cytokines, induce cell inhibition key mechanisms immune escape in HCC. Recently, immunotherapy based on inhibitors (ICIs) monotherapy or combination tyrosine kinase inhibitors, anti-angiogenesis drugs, chemotherapy agents, topical therapies offered great promise treatment cancer. In this review, we discuss latest advances ICIs combined drugs (targeted-immune combination) other targeted-immune regimens patients advanced HCC (aHCC) unresectable (uHCC), provide an outlook future prospects. The literature reviewed spans last five years includes studies identified using keywords "hepatocellular carcinoma," "immune inhibitors," "targeted therapy," "combination "immunotherapy".

Language: Английский

Citations

9

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives DOI Creative Commons
Yuhang Chen,

Suoyi Dai,

Chien‐shan Cheng

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 21, 2024

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism action involves inhibiting signal pathways such as vascular endothelial growth factor receptors (VEGFR) and fibroblast (FGFR), thereby reducing tumor cell proliferation angiogenesis affecting tumor's immune microenvironment. In liver cancer, although lenvatinib monotherapy has shown good clinical effect, problem drug resistance becoming more serious. This may be caused by variety factors, including genetic mutations, signaling pathway remodeling, changes order to overcome resistance, combination other therapeutic strategies gradually become research hotspot, it worth noting that checkpoint inhibitors (ICIs) application prospect. not only enhances anti-tumor response but also helps improve efficacy. However, therapy faces challenges regarding safety tolerability. Therefore, studying mechanisms identifying relevant biomarkers particularly important, aids early diagnosis personalized treatment. article reviews treating efficacy its with inhibitors, causes exploration biomarkers, novel for lenvatinib. We hope provide insights into use scientific settings, offering new cancer.

Language: Английский

Citations

8

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment DOI Creative Commons
Zhenyun Yang, Xin Wang, Yizhen Fu

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 6, 2024

Peritumoral hepatocytes are critical components of the liver cancer microenvironment, However, role peritumoral in local tumor immune interface and underlying molecular mechanisms have not been elucidated. YTHDF2, an RNA N

Language: Английский

Citations

7

Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma—A Retrospective Study DOI
Yue Chen,

Luyao Jia,

Yu Li

et al.

Annals of Surgical Oncology, Journal Year: 2024, Volume and Issue: 31(12), P. 7860 - 7869

Published: Aug. 1, 2024

Language: Английский

Citations

5

Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy DOI Creative Commons
Hongcai Yang,

Tianhao Cong,

Yingen Luo

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 175 - 189

Published: Jan. 1, 2024

Objective: To investigated the association between sarcopenia and prognosis adverse events of hepatocellular carcinoma (HCC) patients undergoing interventional therapy combined with immunotherapy targeted therapy. Methods: Between January 2019 December 2022, unresectable HCC who received were included in this study. Total skeletal muscle area at L3 level was normalized for height m 2 as index (SMI). All divided into low high SMI group according to median SMI. Results: Ninety-six consecutive eventually, 49 high-SMI 47 low-SMI group. In group, overall survival (OS) 459.00 days (95% CI, 334.76– 583.24 days), 3-, 6-, 12-month OS rates 100%, 89.4% 68.1%, respectively. not reached, 98% 79.5%, respectively ( p < 0.05). Barcelona Clinic Liver Cancer (BCLC) C stage independent prognostic factors 26 had treatment-related (TRAEs), resulting dose adjustment or treatment suspension 10 patients. 33 TRAEs, 18 suspension; between-group difference nonsignificant > Conclusion: is associated receiving therapy, an risk factor OS. However, does seem predict occurrence events. Keywords: carcinoma, sarcopenia, immune checkpoint inhibitors, tyrosine kinase transarterial chemoembolization

Language: Английский

Citations

4

Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors DOI Creative Commons
Zhenyun Yang, Renguo Guan, Yizhen Fu

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: Feb. 13, 2024

Background Hepatitis B virus (HBV) reactivation is a common complication in hepatocellular carcinoma (HCC) patients treated with chemotherapy or immunotherapy. This study aimed to evaluate the risk of HBV and its effect on survival HCC HAIC lenvatinib plus PD1s. Methods We retrospectively collected data 213 HBV-related who underwent PD1s treatment between June 2019 2022 at Sun Yat-sen University, China. The primary outcome was reactivation. secondary outcomes were overall (OS), progression−free (PFS), treatment−related adverse events. Results Sixteen (7.5%) occurred our study. incidence 5% antiviral prophylaxis 21.9% without prophylaxis, respectively. logistic regression model indicated that for reactivation, lack ( P =0.003) tumor diameter =0.036) independent factors. OS PFS significantly shorter group than non-reactivation =0.0023 =0.00073, respectively). number AEs more group, especially hepatic AEs. Conclusion may occur Patients had time compared non-reactivation. Therefore, should undergo therapy HBV-DNA monitoring before during combination treatment.

Language: Английский

Citations

4

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and PD-1 Inhibitors for Managing Arterioportal Shunt in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Cohort Study DOI Creative Commons
Guanxiong Liu,

Duo Zhu,

Quansheng He

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 1415 - 1428

Published: July 1, 2024

Purpose: This study aimed to assess the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib (LEN) PD-1 inhibitors in treating arterioportal shunt (APS) hepatocellular carcinoma (HCC) patients portal vein tumor thrombus (PVTT). Patients Methods: Conducted retrospectively, enrolled 54 HCC APS PVTT treated HAIC, LEN, at our center between January 2021 October 2023. improvement, recanalization, response, response rate, overall survival (OS), intrahepatic progression-free (InPFS), adverse events were evaluated. Results: improvement was observed 42 (77.8%), all occurring within two treatment sessions. Complete occlusion achieved 40 (74.1%), no recanalization occurred. The best objective rate (ORR) ORR after HAIC sessions 74.1% 66.7%, respectively. 98.1% 94.4%, median OS InPFS 10.0 months 5.0 months, longer compared those without (OS 12.1 vs 4.4 P< 0.001, 6.2 2.3 P=0.049). ALBI grade, extrahepatic spread, disappearance potential prognostic factors for OS, while grade spread being independently associated InPFS. No treatment-related mortality Conclusion: Combining LEN proves be both effective safe managing PVTT, potentially improving patient survival. Keywords: carcinoma, shunt, thrombus, chemotherapy, combination therapy

Language: Английский

Citations

4